CD8A and non-small cell lung carcinoma: The use of the LDH inhibitor oxamate to reduce lactate production in combination with pembrolizumab significantly increased CD8+ T cell infiltration in a humanized mouse model of non-small cell lung cancer and enhanced the effect of pembrolizumab monotherapy (50).